50
Participants
Start Date
November 30, 2007
Primary Completion Date
March 31, 2010
Study Completion Date
May 31, 2011
KX2-391
2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
Fox Chase Cancer Center, Philadelphia
MD Anderson Cancer Center, Houston
Lead Sponsor
Athenex, Inc.
INDUSTRY